SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Sequent Scientific Limited has informed the Exchange about advertisement published on November 09, 2022, in 'Financial Express' and 'Mumbai Lakshadeep' newspaper providing Extracts of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022 SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the earnings call and earnings presentation made on November 08, 2022, on Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended September 30, 2022, is available on the Company's website
Results Earnings Call for Q2FY23 of Sequent Scientific
Conference Call with Sequent Scientific Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript. Q2FY23 Quarterly Result Announced for Sequent Scientific Ltd.
Pharmaceutical company SeQuent Scientific announced Q2FY23 results: Revenues Rs 3,376 million in Q2FY23 and Rs 6,789 million in H1FY23 EBITDA (pre-ESOP) Rs 150 million in Q2FY23 and Rs 351 million in H1FY23 EBITDA Rs 51 million in Q2FY23 and Rs 161 million in H1FY23 Rajaram Narayanan, Managing Director, stated, “Q2FY23 has been challenging owing to macro environment headwinds even though we continue to see strong performance in select markets. While the overall business grew 2.9% in constant currency terms, the reported revenue declined 3.7% over Q2FY22. EBITDA before ESOP costs stood at Rs 150 million for Q2. Normalised margins (after one-time costs & currency impact) are trending upwards. The API business was subdued due to a slower revival in demand and delays in concluding a few contracts. Our efforts in developing strong partnerships with the top 10 animal health global companies are yielding results and we are confident to restore momentum in this business. We continue to invest in API business across key projects and upgrade our facilities. Our Mahad facility received the prestigious EcoVadis Sustainability Silver Medal and certificate, following by the recent TÜV Nord ISO certifications for Environment, Health & Safety (EHS) in Q1, further validating our commitment to global EHS standards. Our Formulations business grew by 14.8% on constant currency basis, driven by a strong performance in emerging markets and India. We continue to accelerate our efforts in these markets while simultaneously implementing profitability improvement initiatives in our businesses in Europe & Turkey. We continue to believe in SeQuent’s robust business model and are executing on key growth levers. We are pleased to announce that we signed a definitive agreement on November 7, 2022, to acquire 100% stake in Tineta Pharma Pvt Ltd, a company incorporated in India. This acquisition, which is in line with our strategic priority to scale up India formulations business, will be EBITDA accretive and gives a significant boost to our SeQuent 2.0 plans. While the business environment is challenging due to high input costs, currency deterioration in some markets and subdued demand, the company is undertaking multiple initiatives to prioritise growth segments, remain competitive on costs and deepen our engagement with customers. We continue to invest in capabilities and talent required to deliver our ambitious plans and are confident that our initiatives would create a sustainable, long-term advantage for the company as it returns to higher levels of profitable growth.” Result PDF SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Preferential Issue
Sequent Scientific Limited has informed the Exchange that the Board of Directors of the Company at their meeting held today, have inter alia considered and approved the following: 1. Acquisition of entire 100% stake in Tineta Pharma Private Limited ('Tineta') 2. Issuance of equity shares of face value Rs. 2/- each fully paid up of the Company for a value of Rs. 65,00,00,000/- (Rupees Sixty-Five Crores only), at a price not lower than the floor price 3. Amendment to 'SeQuent Scientific Limited Employees Stock Option Plan, 2020' (ESOP Scheme), subject to approval of the shareholders. 4. Postal Ballot notice. SEQUENT SCIENTIFIC LTD. - 512529 - Outcome Of Board Meeting Held On November 07, 2022, Along With Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2022 And Press Release
Sequent Scientific Limited has informed the Exchange that the Board of Directors of the Company at their meeting held today, have inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2022. SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 07, 2022, Along With Unaudited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2022 And Press Release.
Sequent Scientific Limited has informed the Exchange that the Board of Directors of the Company at their meeting held today, have inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2022. SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Acquisition
Sequent Scientific Limited has informed the Exchange that the Board of Directors of the Company at their meeting held today, have inter alia considered and approved the following: 1. Acquisition of entire 100% stake in Tineta Pharma Private Limited ('Tineta') 2. Issuance of equity shares of face value Rs. 2/- each fully paid up of the Company for a value of Rs. 65,00,00,000/- (Rupees Sixty-Five Crores only), at a price not lower than the floor price 3. Amendment to 'SeQuent Scientific Limited Employees Stock Option Plan, 2020' (ESOP Scheme), subject to approval of the shareholders. 4. Postal Ballot notice. SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly note that the Company has, as a part of its investors engagement activities, scheduled a conference call with the Analysts / Investors on Tuesday, November 08, 2022, to discuss its Q2FY23 financial results. SEQUENT SCIENTIFIC LTD. - 512529 - Update on board meeting
SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 ,inter alia, to consider and approve Further to our intimation dated November 1, 2022 regarding the Board Meeting of the Company scheduled for November 7, 2022 to consider and approve the un- audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2022, we wish to inform you that the Board will also evaluate a proposal for the issuance of equity shares through preferential issue to Persons other than Promoters, in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act, 2013, as amended.